⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 15, 2025Open Access

Figure S10 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer

Tianyu Qu Lei Song Jiali Xu Xiyi Lu Dandan Yin Jiali Dai Chen Zhang Renhua Guo Erbao Zhang

View Full Paper

Ask AI

Bookmark

Share

Key Points

MYLK-AS1 enhances glutamine metabolism, contributing to EGFR inhibitor resistance in lung cancer.
Key evidence shows that regulating GLUD1 is crucial for TKI resistance, boosting survival rates under treatment.
The approach involved examining MYLK-AS1's role in glutamine metabolism within non-small cell lung cancer cells.
These findings highlight the need to consider MYLK-AS1 in strategies targeting TKI resistance for better clinical outcomes.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Observational analysis reveals MYLK-AS1 enhances glutamine metabolism in non-small cell lung cancer, indicating a role in TKI resistance.

Abstract

MYLK-AS1 promotes TKI resistance of lung cancer by regulating GLUD1.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Qu et al. (2025) studied this question.

synapsesocial.com/papers/68af6203ad7bf08b1eae2e1c https://doi.org/10.1158/0008-5472.29919066

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S5 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
2Figure S7 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
3Figure S4 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
4Figure S1 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
5Figure S9 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025